Skip to main content
. 2019 Nov 21;9(12):2149–2158. doi: 10.1002/2211-5463.12753

Figure 3.

Figure 3

Plasma EV miRNA expression signature for LUAD diagnosis in the validation phase. (A–C) The expression of miR‐451a, miR‐194‐5p, and miR‐486‐5p in the plasma EVs from patients with LUAD (N = 389) and normal samples from healthy volunteers (N = 104) by qRT‐PCR. (D) ROC curve analysis for miR‐451a, miR‐194‐5p, and miR‐486‐5p in plasma EVs from patients with LUAD (N = 389) and normal samples from healthy volunteers (N = 104). (E) ROC curve analysis for the combined miRNA panel in plasma EVs from patients with LUAD (N = 389) and normal samples from healthy volunteers (N = 104). (F–H) The expression of miR‐451a, miR‐194‐5p, and miR‐486‐5p in plasma EVs from patients with stage I/II LUAD (N = 310) (stage I/II) and normal samples from healthy volunteers (N = 104) (HV) by qRT‐PCR. (I) ROC curve analysis for miR‐451a, miR‐194‐5p, and miR‐486‐5p in plasma EVs from patients with stage I/II LUAD (N = 310) and normal samples from healthy volunteers (N = 104). (J) ROC curve analysis for the combined miRNA panel in plasma EVs from patients with stage I/II LUAD (N = 310) and normal samples from healthy volunteers (N = 104). Each value is the mean ± SD; ***P < 0.001.